There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dermira (DERM), Aduro BioTech (ADRO) and Clovis Oncology (CLVS) with bullish sentiments.
Dermira (DERM)
In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Dermira, with a price target of $22. The company’s shares closed yesterday at $10.50.
According to TipRanks.com, Tsao is a 3-star analyst with an average return of 2.6% and a 53.4% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals Inc, Revance Therapeutics, and Coherus Biosciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Dermira with a $22.14 average price target, which is an 110.9% upside from current levels. In a report issued on April 26, Cantor Fitzgerald also maintained a Buy rating on the stock with a $25 price target.
See today’s analyst top recommended stocks >>
Aduro BioTech (ADRO)
H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Aduro BioTech today and set a price target of $7. The company’s shares closed yesterday at $4.41.
Pantginis observed:
“Valuation and risks to price target achievement. We maintain our Buy rating and $7 price target. The STING program currently contributes approximately 53% to our valuation (no contribution from early stage Lilly program currently) and the APRIL program approximately 43%, with the remainder coming from the anti-CD27 program being developed by Merck (MRK; not rated). Our target is based on our clinical net present value (NPV) model. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile.”
According to TipRanks.com, Pantginis is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -2.4% and a 36.6% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics Inc, and Checkpoint Therapeutics Inc.
Aduro BioTech has an analyst consensus of Strong Buy, with a price target consensus of $7.33, a 66.2% upside from current levels. In a report released today, Cowen & Co. also maintained a Buy rating on the stock.
Clovis Oncology (CLVS)
In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Clovis Oncology, with a price target of $36. The company’s shares closed yesterday at $19.46.
White said:
“We are lowering our price target to $36, from $37, due to our increased diluted share count assumption. We derive our $36 price target from a sum-of-the-parts analysis based on probability-adjusted revenue forecasts for Rubraca in ovarian cancer combination and prostate cancer indications, and the net present value (NPV) for the current commercial business. We use the NPV of our revenue forecasts through 2028, apply a 40% probability of success (POS) for Rubraca in ovarian combination, and a 45% POS for Rubraca in prostate cancer.”
According to TipRanks.com, White is a 5-star analyst with an average return of 14.7% and a 50.0% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Aileron Therapeutics Inc.
Clovis Oncology has an analyst consensus of Moderate Buy, with a price target consensus of $69.20.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
